Mr Richard E Fenn, CRNA | |
1338 Phay Ave, Canon City, CO 81212-2302 | |
(719) 285-2434 | |
(719) 285-2101 |
Full Name | Mr Richard E Fenn |
---|---|
Gender | Male |
Speciality | Certified Registered Nurse Anesthetist (crna) |
Experience | 12 Years |
Location | 1338 Phay Ave, Canon City, Colorado |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1164782769 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
367500000X | Nurse Anesthetist, Certified Registered | 204743 (Colorado) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Centura Health-st Thomas More Hospital | Canon city, CO | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Peak Gastroenterology Associates | 2961484365 | 25 |
Us Anesthesia Partners Of Colorado Inc | 6002072055 | 570 |
Digestive Diseases Specialists Of Colorado,llc | 8527022060 | 5 |
News Archive
Alimera Sciences, Inc., a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced that Alimera Sciences Limited, its European subsidiary based in London, revealed interim six-month data on ILUVIEN (Fluocinolone Acetonide 190 micrograms intravitreal implant in applicator) from the ongoing study referred to as RESPOND, a non-Randomised, open-label, multicenter phase 4 pilot study on the Effect and Safety of ILUVIEN Fluocinolone Acetonide in chronic diabetic macular edema Patients cOnsidered iNsufficiently responsive to available therapies with or without intravitreal corticosteroiD therapy.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that U.S. and European (France, Germany, Italy, Spain and U.K.) sales of Roche/Biogen Idec's Rituxan/MabThera, Bristol-Myers Squibb/Merck's Erbitux and Roche's Herceptin will peak at almost $16 billion in 2014, before falling to roughly $10 billion in 2018.
Robots in the cath lab are helping clear blocked arteries in patients — reducing chest pain, shortness of breath, and risks for heart attacks. The Orlando Health Heart Institute is the first in the state of Florida, to offer a robotic-assisted system for coronary angioplasty.
A new study has shown that poor sleep as a person reaches middle age could mean that the brain is prematurely ageing, equivalent to a decline of up to seven years.
› Verified 5 days ago
Entity Name | Catholic Health Initiatives Colorado |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1356783351 PECOS PAC ID: 8022927342 Enrollment ID: O20031215000462 |
News Archive
Alimera Sciences, Inc., a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced that Alimera Sciences Limited, its European subsidiary based in London, revealed interim six-month data on ILUVIEN (Fluocinolone Acetonide 190 micrograms intravitreal implant in applicator) from the ongoing study referred to as RESPOND, a non-Randomised, open-label, multicenter phase 4 pilot study on the Effect and Safety of ILUVIEN Fluocinolone Acetonide in chronic diabetic macular edema Patients cOnsidered iNsufficiently responsive to available therapies with or without intravitreal corticosteroiD therapy.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that U.S. and European (France, Germany, Italy, Spain and U.K.) sales of Roche/Biogen Idec's Rituxan/MabThera, Bristol-Myers Squibb/Merck's Erbitux and Roche's Herceptin will peak at almost $16 billion in 2014, before falling to roughly $10 billion in 2018.
Robots in the cath lab are helping clear blocked arteries in patients — reducing chest pain, shortness of breath, and risks for heart attacks. The Orlando Health Heart Institute is the first in the state of Florida, to offer a robotic-assisted system for coronary angioplasty.
A new study has shown that poor sleep as a person reaches middle age could mean that the brain is prematurely ageing, equivalent to a decline of up to seven years.
› Verified 5 days ago
Entity Name | Anesthesia & Pain Management Services Of Pueblo |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1639255409 PECOS PAC ID: 2961301783 Enrollment ID: O20031231000222 |
News Archive
Alimera Sciences, Inc., a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced that Alimera Sciences Limited, its European subsidiary based in London, revealed interim six-month data on ILUVIEN (Fluocinolone Acetonide 190 micrograms intravitreal implant in applicator) from the ongoing study referred to as RESPOND, a non-Randomised, open-label, multicenter phase 4 pilot study on the Effect and Safety of ILUVIEN Fluocinolone Acetonide in chronic diabetic macular edema Patients cOnsidered iNsufficiently responsive to available therapies with or without intravitreal corticosteroiD therapy.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that U.S. and European (France, Germany, Italy, Spain and U.K.) sales of Roche/Biogen Idec's Rituxan/MabThera, Bristol-Myers Squibb/Merck's Erbitux and Roche's Herceptin will peak at almost $16 billion in 2014, before falling to roughly $10 billion in 2018.
Robots in the cath lab are helping clear blocked arteries in patients — reducing chest pain, shortness of breath, and risks for heart attacks. The Orlando Health Heart Institute is the first in the state of Florida, to offer a robotic-assisted system for coronary angioplasty.
A new study has shown that poor sleep as a person reaches middle age could mean that the brain is prematurely ageing, equivalent to a decline of up to seven years.
› Verified 5 days ago
Entity Name | Peak Gastroenterology Associates |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1023112117 PECOS PAC ID: 2961484365 Enrollment ID: O20040601000848 |
News Archive
Alimera Sciences, Inc., a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced that Alimera Sciences Limited, its European subsidiary based in London, revealed interim six-month data on ILUVIEN (Fluocinolone Acetonide 190 micrograms intravitreal implant in applicator) from the ongoing study referred to as RESPOND, a non-Randomised, open-label, multicenter phase 4 pilot study on the Effect and Safety of ILUVIEN Fluocinolone Acetonide in chronic diabetic macular edema Patients cOnsidered iNsufficiently responsive to available therapies with or without intravitreal corticosteroiD therapy.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that U.S. and European (France, Germany, Italy, Spain and U.K.) sales of Roche/Biogen Idec's Rituxan/MabThera, Bristol-Myers Squibb/Merck's Erbitux and Roche's Herceptin will peak at almost $16 billion in 2014, before falling to roughly $10 billion in 2018.
Robots in the cath lab are helping clear blocked arteries in patients — reducing chest pain, shortness of breath, and risks for heart attacks. The Orlando Health Heart Institute is the first in the state of Florida, to offer a robotic-assisted system for coronary angioplasty.
A new study has shown that poor sleep as a person reaches middle age could mean that the brain is prematurely ageing, equivalent to a decline of up to seven years.
› Verified 5 days ago
Entity Name | Digestive Diseases Specialists Of Colorado,llc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1033135330 PECOS PAC ID: 8527022060 Enrollment ID: O20041115001261 |
News Archive
Alimera Sciences, Inc., a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced that Alimera Sciences Limited, its European subsidiary based in London, revealed interim six-month data on ILUVIEN (Fluocinolone Acetonide 190 micrograms intravitreal implant in applicator) from the ongoing study referred to as RESPOND, a non-Randomised, open-label, multicenter phase 4 pilot study on the Effect and Safety of ILUVIEN Fluocinolone Acetonide in chronic diabetic macular edema Patients cOnsidered iNsufficiently responsive to available therapies with or without intravitreal corticosteroiD therapy.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that U.S. and European (France, Germany, Italy, Spain and U.K.) sales of Roche/Biogen Idec's Rituxan/MabThera, Bristol-Myers Squibb/Merck's Erbitux and Roche's Herceptin will peak at almost $16 billion in 2014, before falling to roughly $10 billion in 2018.
Robots in the cath lab are helping clear blocked arteries in patients — reducing chest pain, shortness of breath, and risks for heart attacks. The Orlando Health Heart Institute is the first in the state of Florida, to offer a robotic-assisted system for coronary angioplasty.
A new study has shown that poor sleep as a person reaches middle age could mean that the brain is prematurely ageing, equivalent to a decline of up to seven years.
› Verified 5 days ago
Entity Name | Us Anesthesia Partners Of Colorado Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1922365782 PECOS PAC ID: 6002072055 Enrollment ID: O20120725000032 |
News Archive
Alimera Sciences, Inc., a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced that Alimera Sciences Limited, its European subsidiary based in London, revealed interim six-month data on ILUVIEN (Fluocinolone Acetonide 190 micrograms intravitreal implant in applicator) from the ongoing study referred to as RESPOND, a non-Randomised, open-label, multicenter phase 4 pilot study on the Effect and Safety of ILUVIEN Fluocinolone Acetonide in chronic diabetic macular edema Patients cOnsidered iNsufficiently responsive to available therapies with or without intravitreal corticosteroiD therapy.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that U.S. and European (France, Germany, Italy, Spain and U.K.) sales of Roche/Biogen Idec's Rituxan/MabThera, Bristol-Myers Squibb/Merck's Erbitux and Roche's Herceptin will peak at almost $16 billion in 2014, before falling to roughly $10 billion in 2018.
Robots in the cath lab are helping clear blocked arteries in patients — reducing chest pain, shortness of breath, and risks for heart attacks. The Orlando Health Heart Institute is the first in the state of Florida, to offer a robotic-assisted system for coronary angioplasty.
A new study has shown that poor sleep as a person reaches middle age could mean that the brain is prematurely ageing, equivalent to a decline of up to seven years.
› Verified 5 days ago
Mailing Address | Practice Location Address |
---|---|
Mr Richard E Fenn, CRNA 1338 Phay Ave, Canon City, CO 81212-2302 Ph: (719) 285-2434 | Mr Richard E Fenn, CRNA 1338 Phay Ave, Canon City, CO 81212-2302 Ph: (719) 285-2434 |
News Archive
Alimera Sciences, Inc., a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, announced that Alimera Sciences Limited, its European subsidiary based in London, revealed interim six-month data on ILUVIEN (Fluocinolone Acetonide 190 micrograms intravitreal implant in applicator) from the ongoing study referred to as RESPOND, a non-Randomised, open-label, multicenter phase 4 pilot study on the Effect and Safety of ILUVIEN Fluocinolone Acetonide in chronic diabetic macular edema Patients cOnsidered iNsufficiently responsive to available therapies with or without intravitreal corticosteroiD therapy.
Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, forecasts that U.S. and European (France, Germany, Italy, Spain and U.K.) sales of Roche/Biogen Idec's Rituxan/MabThera, Bristol-Myers Squibb/Merck's Erbitux and Roche's Herceptin will peak at almost $16 billion in 2014, before falling to roughly $10 billion in 2018.
Robots in the cath lab are helping clear blocked arteries in patients — reducing chest pain, shortness of breath, and risks for heart attacks. The Orlando Health Heart Institute is the first in the state of Florida, to offer a robotic-assisted system for coronary angioplasty.
A new study has shown that poor sleep as a person reaches middle age could mean that the brain is prematurely ageing, equivalent to a decline of up to seven years.
› Verified 5 days ago
Theresa Diane Keefer, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1338 Phay Ave, Canon City, CO 81212 Phone: 719-285-2861 Fax: 719-285-2101 | |
Mrs. Teri Y Alberty, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1338 Phay Ave, Canon City, CO 81212 Phone: 719-285-2434 Fax: 719-285-2101 | |
Darran Dee Sawyer, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1338 Phay Ave, Canon City, CO 81212 Phone: 719-285-2861 Fax: 719-285-2101 | |
Lisa G Pearson, DNAP, CRNA, NSPMC Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 113 Latigo Lane, Suite D, Canon City, CO 81212 Phone: 719-371-0000 | |
Larry Steven Mcmillen, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 933 Sells Ave, Canon City, CO 81212 Phone: 719-275-6433 | |
Ms. Kelly Gilkerson, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1338 Phay Ave, Canon City, CO 81212 Phone: 719-285-2861 Fax: 719-285-2101 |